1-3 of 3
Mohamed Rahmani, PhD
Close
Sort by
Journal Articles

Role of the PI3K Pathway in the Pathogenesis of Marginal Zone Lymphoma

Ariel Sindel, DO, Ian McConnell, MS, Jolene Windle, PhD, Roy Sabo, PhD, Alden Chesney, MD, Guanhua Lai, MD PhD, Adolfo Mauro, PhD, Taha Al-Juhaishi, MD, Mohamed Rahmani, PhD, Jamal Zweit, PhD, Steven Grant, MD, Steven Grossman, MD, Victor Youssef Yazbeck, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4125.
https://doi.org/10.1182/blood-2018-99-111284
Published: 2018
Journal Articles

Gls Inhibitor CB-839 Modulates Cellular Metabolism in AML and Potently Suppresses AML Cell Growth When Combined with 5-Azacitidine

Tianyu Cai, PhD, Philip L Lorenzi, PhD, Dinesh Rakheja, MD, Michael A Pontikos, Alessia Lodi, Lina Han, MD PhD, Qi Zhang, MD PhD, Helen Ma, MS, Mohamed Rahmani, PhD, Tushar Damodar Bhagat, PhD, Thomas D Horvath, PhD, Courtney D. DiNardo, MD MSCE, Steven Grant, MD, Stefano Tiziani, PhD, Amit Verma, MD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4064.
https://doi.org/10.1182/blood.V128.22.4064.4064
Published: 2016
Journal Articles

Co-Administration of the mTORC1/TORC2 Inhibitor INK128 and the Bcl-2/Bcl-Xl Antagonist ABT-737 Kills Human Myeloid Leukemia Cells through Mcl-1 Down-Regulation and AKT Inactivation

Mohamed Rahmani, PhD, Mandy Mayo Aust, Elisa Hawkins, Rebecca E Parker, Leonid Reshko, Masey Ross, MD, Maciej Kmieciak, PhD, Kathryn Ann Rizzo, DO, PhD, Catherine I Dumur, PhD, Andrea Ferreira-Gonzalez, PhD, Steven Grant, MD
Journal: Blood
Blood (2015) 126 (23): 3676.
https://doi.org/10.1182/blood.V126.23.3676.3676
Published: 2015